Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Chronic cough stories

Jul 17, 2026

GSK halts development of chronic cough drug after late-stage trial failures

GSK discontinued development of an experimental chronic cough treatment after it failed to meet key goals in two late-stage clinical trials, with the company stating it was unlikely to transform patient care. Shares fell about 4%.

Jul 17, 2026·2 sources
00

Top claims

  • ▪GSK will halt the development of its experimental drug, camlipixant, for treating refractory chronic cough.
  • ▪GSK had forecasted peak annual sales of about £2.5 billion for camlipixant, though analyst estimates were closer to £1 billion.
  • ▪Following the announcement on July 17, 2026, GSK's shares fell by as much as 4.5%.

Topics

Clinical trialsPharmaceutical Industry

Featured Stories

OpenAI pauses development of Astra AI model over critical cybersecurity capability concerns

OpenAI pauses development of Astra AI model over critical cybersecurity capability concerns

Aug 7, 2026·2 sources